The approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc's reference listed drug (RLD), Apriso extended-release capsules, 0.375 g, it added. The drug has an estimated market size of USD 133 million for the months ended June 2022, Alembic said citing IQVIA data.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xBfvnqP
via IFTTT
0 comments:
Post a Comment